Skip to content

EBIT at other companies

Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-$17.43M+85.6%
AdaptHealth logo
AdaptHealthAHCO
$5.49M-76.3%
Insulet logo
InsuletPODD
Medtronic logo
MedtronicMDT
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO

Other financials

Income statement

See full
Revenue$27.6M+56.6%
Gross profit$16.4M+83.2%
Operating income-$24.3M-30.2%
Net income-$21.9M+23.6%
EPS (diluted)-$0.49+47.3%

Balance sheet

See full
Cash & equivalents$30.2M-28.9%
Total debt$6.9M-0.9%
Total equity$271.2M-13.5%
Total assets$304.4M-9.9%

Cash flow

See full
Operating cash flow-$23.8M-19.3%
CapEx$1.4M+314%
Free cash flow-$25.2M-24.1%

Valuation

See full
Market cap$708.98M-8.6%
Enterprise value$685.68M
P/S6.4×

Profitability

See full
Gross margin57.2%+3.2pp
Operating margin-70.1%-6.4pp
Net margin-60.3%-17.4pp
FCF margin-55.4%-14.3pp

Returns & leverage

See full
Return on equity-22.7%
Debt / equity0.0×
Current ratio10.7×-5.2×

Where this comes from

Calculated from BBNX’s reported figures.

The official record: BBNX’s 10-Q, filed April 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about BBNX's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BBNX's EBIT?
BBNX (BBNX) reported EBIT of -$24.27M in Q1 2026.
How has BBNX's EBIT changed year-over-year?
BBNX's EBIT decreased by 30.2% year-over-year, from -$18.64M to -$24.27M.
What is the long-term trend for BBNX's EBIT?
Over 2 years (2023 to 2025), BBNX's EBIT has grown at a 41.4% compound annual growth rate (CAGR), from -$35.85M to -$71.68M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.